SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor (OPEN) is trending due to a mixed earnings report and the announcement of warrant distribution to shareholders, sparking debate about its impact. The community is discussing the implications of these warrants, potential partnerships (especially with Robinhood), and the company's shift towards AI and tokenization. Bearish sentiment revolves around cost structure, market volatility, and dilution, while bulls are optimistic about new leadership and long-term growth.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending amid community excitement around its potential as an AI and Web3 infrastructure play, particularly with the launch of the Caffeine AI platform. Community members are comparing it to Zcash, speculating on price targets like $100, and discussing its potential to challenge major cloud providers. Some traders are noting its decoupling from Bitcoin's price action and highlighting its utility.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending due to a surge in interest in privacy coins, with community members highlighting its potential for significant gains and comparing it favorably to Bitcoin. The community is actively discussing price targets and whether to hold or take profits, while also debating its privacy features and potential for mainstream adoption. Some believe ZEC could reach new all-time highs, while others caution about a potential pullback after its recent surge.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Despite strong revenue growth and an earnings beat, CELH is trending down, sparking community debate around the impact of a one-time distributor termination fee and guidance for the next quarter. Some investors view the dip as a buying opportunity, drawing comparisons to successful consumer plays like Coca-Cola and highlighting the company's growth potential, especially with PepsiCo's distribution network. Others express concern over short-term volatility and potential market overreaction.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending with mixed sentiment as the community debates recent price action, with some labeling it a "sucker coin" and others anticipating a rally. Discussions include potential catalysts like FED rate cuts and broader crypto market trends, but many are warning of further downside. Technical analysis and identification of chart patterns are also being discussed.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SOUN is trending as investors discuss its recent earnings, with some calling it a buying opportunity while others express concerns about market manipulation and the broader economic climate. Community members are debating the company's growth prospects, particularly in light of new deals and partnerships, and its path to profitability. The stock's volatile price action and correlation to the overall market are also key points of discussion.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation ($ACHR) is trending amid discussions about a potential partnership with Tesla ($TSLA) following Elon Musk's hints about flying cars; community members are analyzing the likelihood of collaboration given existing manufacturing partnerships. Recent news includes Archer's acquisition of Hawthorne Airport near SpaceX, sparking speculation about synergies, while a secondary offering has fueled concerns about dilution and management's commitment to shareholders.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

TTWO is trending as investors digest news of a 'GTA 6' delay to November 2026, despite a recent profit beat, prompting debate about the game's development status. Community sentiment is mixed, with some viewing the dip as a buying opportunity based on long-term potential, while others express concerns about the delay's impact and potential downgrades. Broader market worries about consumer spending and the video game sector's performance add another layer to the discussion.

The Filecoin network achieves staggering economies of scale by allowing anyone worldwide to participate as storage providers. It also makes storage resemble a commodity or utility by decoupling hard-drive space from additional services. On this robust global market the price of storage will be driven by supply and demand, not corporate pricing departments, and miners will compete on factors like reputation for reliability as well as price.

Filecoin

Filecoin (FIL) is experiencing increased attention as discussions swirl around potential catalysts and its role in decentralized storage, AI, and DePIN narratives. The community is actively debating entry points, long-term potential, and comparing FIL to competitors like Zcash and new protocols such as Walrus. While some express frustration with past performance, others remain optimistic about future growth amid developments in the decentralized web.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly ($LLY) is trending due to a mix of factors, including positive weight-loss drug data and strategic moves like partnering with Walmart for direct-to-consumer Zepbound sales. The community is actively discussing the potential impact of these developments on the company's market position and future growth, especially in light of the competitive landscape with companies like Novo Nordisk. Additionally, potential deals with the Trump administration to cut weight loss drug prices, may impact the profitabilty in the GLP-1 market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pfizer (NYSE:PFE) Stock Price Up 1.3% - Still a Buy?

Pfizer (NYSE:PFE) Trading 1.3% Higher - Still a Buy...

Top Dividend Stocks To Research - November 5th

Direxion Daily TSLA Bull 2X Shares, Pfizer, ProShares UltraPro Short QQQ, Amgen, and AT&T are the five Dividend stocks to watch today, according to MarketBeat's stock screener tool. Dividend stocks...

Top Pharmaceutical Stocks To Add to Your Watchlist - November 6th

Eli Lilly and Company, Pfizer, Novo Nordisk A/S, 89BIO, McKesson, AbbVie, and Teva Pharmaceutical Industries are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock...

Medical Stocks To Watch Now - November 6th

Eli Lilly and Company, Pfizer, Novo Nordisk A/S, UnitedHealth Group, and Hims & Hers Health are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. "Medical stocks...

Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans

MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment

AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs Outperform

AstraZeneca posts strong Q3 results. Core earnings and revenues beat estimates as key drugs like Tagrisso, Imfinzi and Farxiga fuel broad-based growth.

<ul class="summary-bullets"><li>The details of the new bid could not be immediately ascertained, FT said.</li><li>Pfizer now has two days to match Novo’s bid or let its agreed-upon deal with Metsera fall through, the report stated.&nbsp;</li><li>Pfizer reportedly matched Novo’s last offer late on Wednesday, prompting Novo’s new bid. &nbsp;</li></ul>Danish drugmaker Novo Nordisk has reportedly sweetened its bid further for obesity drug maker Metsera amid a rising bidding war with Pfizer.The Financial Times<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/52216b29-9f22-4338-85a7-eacfc33103a1"> reported</a> on Thursday, citing people familiar with the matter, that Novo raised its bid after Pfizer matched its last offer, valuing the company at up to $10 billion, late on Wednesday.The details of the new bid could not be immediately ascertained, FT said. Pfizer now has two days to match Novo’s bid or let its agreed-upon deal with Metsera fall through, the report stated.&nbsp;<h2 class="st-heading-2">Start Of The Bidding War</h2>Novo Nordisk first announced last week that it has submitted an unsolicited proposal to acquire Metsera, following Pfizer's agreement to acquire the smaller obesity biopharmaceutical company in September. Metsera determined that Novo’s bid was superior and gave Pfizer a certain number of days to negotiate the terms of their agreement. &nbsp;On Monday, Metsera said that it has received revised bids from both Pfizer and Novo, valuing the company at up to $8.1 billion and $10 billion, respectively. Pfizer reportedly matched Novo’s offer late on Wednesday, prompting Novo’s new bid.Pfizer had requested a temporary restraining order from the Delaware Chancery Court last week to prevent Metsera from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk. However, the court denied the request on Wednesday. Pfizer, however, said that it intends to pursue further litigation and expressed confidence in the merit of claims that Metsera has acted in breach of its contractual obligations. Metsera, on its side, dismissed Pfizer’s arguments as “nonsense.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/MTSR">MTSR stock</a> soared 14% at the time of writing. On Stocktwits, retail sentiment around MTSR stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.MTSR stock has more than tripled this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/johnson-and-johnson-newly-acquired-antipsychotic-drug-approved-by-fda-for-major-depressive-disorder/cL2tuwZRERN">Johnson &amp; Johnson’s Newly Acquired Antipsychotic Drug Approved By FDA For Major Depressive Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Metsera logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further

According to an FT report, Pfizer now has two days to match Novo’s new bid or let its agreed-upon deal with Metsera fall through. 

Equity

Leerink Partnrs Issues Negative Outlook for Pfizer Earnings

Pfizer Inc. (NYSE:PFE - Free Report) - Analysts at Leerink Partnrs reduced their Q4 2025 earnings estimates for shares of Pfizer in a research report issued to clients and investors on Tuesday...

Twin Capital Management Inc. Acquires 26,118 Shares of Pfizer Inc. $PFE

Twin Capital Management Inc. lifted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 39.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and...

<ul class="summary-bullets"><li>Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera.</li><li>The court decision follows Metsera’s board reaffirming Novo’s revised $86.20-per-share offer as superior to Pfizer’s $8.1 billion counterproposal.</li><li>Pfizer vowed to continue its legal and antitrust challenges in Delaware federal court.</li></ul>Novo Nordisk’s U.S.-listed shares rose Wednesday, ending an 11-session losing streak, after a Delaware judge rejected Pfizer's request to block the Danish company’s $10 billion acquisition of obesity-drug startup Metsera Inc.Delaware Chancery Judge Morgan Zurn said Pfizer’s objections didn’t warrant delaying the transaction and found no evidence Metsera’s board acted in bad faith when it labeled Novo’s offer “superior.” The ruling allows Novo to proceed with the deal, which topped Pfizer’s earlier $4.9 billion agreement announced in September, according to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-11-05/pfizer-loses-legal-bid-to-temporarily-block-novo-s-metsera-offer">report</a>.<h2 class="st-heading-2">Revised Offers Raise The Stakes</h2>On Tuesday, Metsera said it received a revised offer from Novo valuing the company at up to $86.20 per share, or about $10 billion. The new proposal includes $62.20 per share in cash, up from $56.50 in the original bid, plus contingent value rights worth up to $24.00 per share if certain milestones are achieved.Pfizer also revised its terms, increasing upfront consideration to $60 per share and trimming the contingent payout to $10 per share, valuing its bid at roughly $8.1 billion. Despite the adjustment, Metsera’s board reaffirmed Novo’s offer as superior and gave Pfizer two business days to counter before terminating its merger agreement.<h2 class="st-heading-2">Pfizer Vows To Keep Fighting</h2>Pfizer said the ruling “fails to address the legal issues raised” and vowed to continue litigation in Delaware federal court, calling Novo’s bid “an unprecedented and illegal scheme to circumvent antitrust scrutiny.” The company alleges Novo’s move is designed to protect its dominance in the GLP-1 obesity-drug space by neutralizing a future competitor.Novo countered that the court’s ruling validates its approach and serves shareholders’ best interests. Its offer, which includes both upfront and milestone-based payments, aims to bring Metsera’s experimental weight-loss portfolio, which is a potential rival to Ozempic and Wegovy, under its umbrella.<h2 class="st-heading-2">FTC Flags Premerger Concerns</h2>The U.S. Federal Trade Commission warned that Novo’s offer could breach the Hart-Scott-Rodino Act if completed without premerger review. In a Nov. 4 letter, the FTC said the structure of Novo’s bid, which grants substantial upfront payments before regulatory approval, could reduce Metsera’s independence and incentive to pursue its drug pipeline.<h2 class="st-heading-2">Stocktwits Bulls Cheer, Bears Question The Deal</h2>On Stocktwits, retail sentiment for Novo Nordisk was ‘extremely bullish’ amid a 159% jump in 24-hour message volume.<figure class="image"><img style="aspect-ratio:964/138;" src="https://news.stocktwits-cdn.com/nvo_ss_jpg_016bd02a5d.webp" alt="nvo ss.jpg" width="964" height="138"><figcaption>NVO sentiment and message volume as of November 5 | Source: Stocktwits</figcaption></figure>One user suggested that better days could be close, urging others to “hold strong.”<stembedurl>https://stocktwits.com/RunGoodStreakAlive/message/635121830</stembedurl>Another user, however, questioned whether Novo’s management understood investor sentiment, noting that Pfizer’s stock tends to rise each time it appears closer to reclaiming the Metsera deal, suggesting that shareholders aren’t convinced by Novo’s acquisition push.<stembedurl>https://stocktwits.com/GreenHawkz/message/635102183</stembedurl><a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s U.S.-listed stock</a> has declined 43% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Novo Nordisk Snaps 11-Day Losing Streak After Court Rejects Pfizer’s Challenge To $10B Metsera Deal

Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera.

$PFE Q3 &#39;25 Earnings Results &amp; Recap 
 
Pfizer reported Q3 2025 revenues of $16.7 billion versus an estimate of $16.5B, with an adjusted EPS of $0.87, exceeding estimates of $0.63; the company is raising its full-year adjusted diluted EPS guidance to $3.00-$3.15.

Stocktwits

Pfizer Inc

 Q3 '25 Earnings Results & Recap 
 
Pfizer reported Q3 2025 revenues of $16.7 billion versus an estimate of $16.5B, with an adjusted EPS of $0.87, exceeding estimates of $0.63; the company is raising its full-year adjusted diluted EPS guidance to $3.00-$3.15.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

$HOOD

$ELF

$DUOL

$CELH

Which of these post-earnings decliners are you most interested in buying?

Current Price	$24.90
Prev Close	$24.61
Open	$24.75
Dividend Yield	6.37%
50-Day Moving Average	$24.74
Beta	0.41
Avg. Volume	61.31M
PE Ratio	14.48

52-Week High	$27.69
52-Week Low	$20.92
Market Capitalization	$141.29B
EPS (Annual)	$1.41
Price to Book	1.52
Revenue Per Employee	$785,518.52
Enterprise Value/EBITDA	N/A

PFE
Pfizer Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PFE News

PFEPfizer Inc